Year-over-year earnings per share growth for the last twelve months: Replimune Group, Inc. (REPL)

replimune.com (REPL) - corporate logo

Replimune Group, Inc. (REPL) is taking risks in the scientific race to develop oncolytic viruses, yet its breakthrough melanoma treatments are nearing regulatory approval. Development relies on external contractors alongside partial in-house production. This quarterly EPS trend on GURU.Markets reflects the current trajectory, with the latest value recorded as 39.80.

Replimune Group Inc (REPL) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Replimune Inc. (REPL)

- share price and expert price forecast:
Stock Price Replimune|REPL - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Replimune Corp|REPL - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Replimune|REPL - Company Net Assets|Market Cap to Net Assets Ratio replimune.com|REPL - Company Total Assets
- debt and liquidity details:
Debt to Equity Replimune Group, Inc.|REPL - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Replimune Group, Inc.|REPL - Company Cumulative Debt|Debt to Book Value Replimune Corp|REPL - Long-Term Indebtedness|Company Current Liabilities Replimune|Quick Ratio replimune.com
- earnings and market multiples details:
REPL - Final Profit|Projected Future Earnings Replimune Group, Inc.|REPL - Market Cap to Earnings|Future Price to Earnings Replimune Corp|REPL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Replimune Corp|REPL - Operating profit EBITDA|Earnings per share for the last twelve months Replimune|REPL - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months replimune.com|REPL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Replimune Group, Inc.
Comprehensive company analysis:Replimune, REPL
Manufactured product of Replimune Group, Inc.

Professional managers filter assets based on the dynamics of real business returns. This metric measures the rate of change in net income per share, identifying capital management efficiency while stripping out market noise. For Replimune Group, Inc. (REPL), such indicators are critical, as the massive costs associated with FDA trials often pressure financial results. Analyzing the percentage change in quarterly EPS allows investors to separate one-time write-offs from systemic growth. This makes the percentage change in quarterly EPS a key filter for the fundamental stability of a biotech company.

Competitors of Replimune Group, Inc.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Lyell Immunopharma (LYEL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months innate-pharma.com (IPHA)|Year-over-year net earnings per share growth for the last 12 months PYXS|CGEN - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months IOBT (IO Biotech Corp)|Year-over-year earnings per share growth rate for the last twelve months STRO|Quarterly EPS earnings growth INKT (MiNK Therapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|INTS - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months SNSE (Sensei Biotherapeutics)|TOVX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Gritstone bio (GRTS)|Year-over-year earnings per share growth for the last twelve months Kineta Bio|NexImmune Corporation - Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics (TSBX)|Year-over-year earnings per share growth for the last twelve months VCNX (vaccinex.com)|Quarterly EPS earnings growth HARP (Harpoon Therapeutics, Inc.)